Charles Schwab
BDTX icon

Charles Schwab’s Black Diamond Therapeutics BDTX Stock Holding History

Charles Schwab’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Buy
107,688
+93,204
+643% +$228K ﹤0.01% 3371
2026
Q1 		$30.9K Hold
14,484
– – ﹤0.01% 3443
2025
Q4 		$35.2K Hold
14,484
– – ﹤0.01% 3442
2025
Q3 		$54.9K Hold
14,484
– – ﹤0.01% 3425
2025
Q2 		$35.9K Sell
14,484
-94,740
-87% -$183K ﹤0.01% 3470
2025
Q1 		$169K Hold
109,224
– – ﹤0.01% 3277
2024
Q4 		$234K Hold
109,224
– – ﹤0.01% 3299
2024
Q3 		$475K Buy
109,224
+7,021
+7% +$38.2K ﹤0.01% 3174
2024
Q2 		$476K Buy
102,203
+87,719
+606% +$471K ﹤0.01% 3215
2024
Q1 		$73.4K Hold
14,484
– – ﹤0.01% 3335
2023
Q4 		$40.7K Hold
14,484
– – ﹤0.01% 3421
2023
Q3 		$41.6K Hold
14,484
– – ﹤0.01% 3422
2023
Q2 		$73.1K Buy
+14,484
New +$29.6K ﹤0.01% 3373
2022
Q3 		– Sell
-17,994
Closed -$45K – 3512
2022
Q2 		$45K Sell
17,994
-30,293
-63% -$70.4K ﹤0.01% 3405
2022
Q1 		$134K Sell
48,287
-12,026
-20% -$43.9K ﹤0.01% 3372
2021
Q4 		$322K Hold
60,313
– – ﹤0.01% 3270
2021
Q3 		$511K Sell
60,313
-58,270
-49% -$575K ﹤0.01% 3145
2021
Q2 		$1.45M Buy
118,583
+4,077
+4% +$80.6K ﹤0.01% 2812
2021
Q1 		$2.78M Buy
114,506
+6,379
+6% +$172K ﹤0.01% 2556
2020
Q4 		$3.47M Buy
108,127
+1,558
+1% +$51.2K ﹤0.01% 2392
2020
Q3 		$3.22M Buy
106,569
+25,314
+31% +$770K ﹤0.01% 2302
2020
Q2 		$3.43M Buy
81,255
+55,702
+218% +$2.05M ﹤0.01% 2205
2020
Q1 		$638K Buy
+25,553
New +$778K ﹤0.01% 2629

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Charles Schwab's BDTX Position: Q2 2026 in Review

Charles Schwab increased its Black Diamond Therapeutics (BDTX) stake by 643% in Q2 2026, buying an estimated $228K and bringing the position to 107,688 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #3371.

Charles Schwab first reported a position in BDTX in Q1 2020 and has held it in 23 quarters since. The position peaked at $3.47M in Q4 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Charles Schwab held 107,688 shares of Black Diamond Therapeutics worth $199K as of Q2 2026.
  • Charles Schwab bought 93,204 Black Diamond Therapeutics shares in Q2 2026, an estimated $228K.
  • Black Diamond Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3371 holding.
  • Charles Schwab first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • Charles Schwab's Black Diamond Therapeutics position peaked at $3.47M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.